@entity43 is the most lethal gynecologic malignancy in the United States. Although @entity1 initially respond to the current standard of care consisting of surgical debulking and combination chemotherapy consisting of @entity902 and @entity3907 compounds, almost 90% of @entity1 recur within a few years. In these @entity1 the development of chemoresistant disease limits the efficacy of currently available chemotherapy agents and therefore contributes to the high mortality. To discover novel therapy options that can target recurrent disease, appropriate animal models that closely mimic the clinical profile of @entity1 with recurrent @entity43 are required. The challenge in monitoring intra-peritoneal (i.p.) disease limits the use of i.p. models and thus most xenografts are established subcutaneously. We have developed a sensitive optical imaging platform that allows the detection and anatomical location of i.p. @entity5 mass. The platform includes the use of optical reporters that extend from the visible light range to near infrared, which in combination with 2-dimensional X-ray co-registration can provide anatomical location of molecular signals. Detection is significantly improved by the use of a rotation system that drives the animal to multiple angular positions for 360 degree imaging, allowing the identification of @entity5 that are not visible in single orientation. This platform provides a unique model to non-invasively monitor @entity5 growth and evaluate the efficacy of new therapies for the prevention or treatment of recurrent @entity43 .

Murine model for non-invasive imaging to detect and monitor XXXX recurrence.

@entity43 :: ('MESH:D010051', 'Disease') :: ['ovarian cancer', 'Epithelial ovarian cancer'] @entity1 :: ('9606', 'Species') :: ['patients'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'tumors'] @entity3907 :: ('MESH:C080625', 'Chemical') :: ['taxane'] @entity902 :: ('MESH:D010984', 'Chemical') :: ['platinum']
@entity43 :: (MESH:D010051,Disease) :: ['ovarian cancer']
